Canopy Growth (CGC) Cost of Revenue (2019 - 2025)
Canopy Growth (CGC) reported Cost of Revenue of $109.0 million for Q4 2025, up 200.44% on a YoY basis from $36.3 million in Q4 2024, and up 234.88% sequentially from $32.5 million in Q3 2025.
Canopy Growth (CGC) Cost of Revenue (2019 - 2025) Analysis & Trends
Canopy Growth (CGC) has 7 years of Cost of Revenue data on file, last reported at $109.0 million in Q4 2025.
- For the quarter ending Q4 2025, Cost of Revenue rose 200.44% year-over-year to $109.0 million; the trailing twelve-month figure through Dec 2025 stood at $216.8 million (up 54.26% YoY), and the FY2026 full-year result was $156.7 million, up 18.69% from the prior year.
- Cost of Revenue advanced to $109.0 million in Q4 2025, from $32.5 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $174.3 million in Q1 2022 to a low of $30.2 million in Q3 2024.
- A 5-year average of $73.1 million and a median of $58.7 million in 2022 frame the typical range for Cost of Revenue.
- Across the five-year window, Cost of Revenue plunged 57.8% in 2022 and surged 200.44% in 2025, its largest moves.
- Tracing CGC's Cost of Revenue over 5 years: stood at $103.8 million in 2021, then plunged by 43.51% to $58.7 million in 2022, then sank by 37.04% to $36.9 million in 2023, then decreased by 1.8% to $36.3 million in 2024, then surged by 200.44% to $109.0 million in 2025.
- Business Quant data shows CGC's Cost of Revenue at $109.0 million in Q4 2025, $32.5 million in Q3 2025, and $39.0 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 2.01 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 641.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 2.59 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 133.40 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 2.36 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 13.80 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 586.00 Mn |
| 10 | Canopy Growth | 276.52 Mn | 10.60 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 108.96 Mn |
| Dec 31, 2025 | 108.96 Mn |
| Sep 30, 2025 | 32.54 Mn |
| Sep 30, 2025 | 32.54 Mn |
| Jun 30, 2025 | 39.04 Mn |
| Jun 30, 2025 | 39.04 Mn |
| Dec 31, 2024 | 36.27 Mn |
| Dec 31, 2024 | 36.27 Mn |
| Sep 30, 2024 | 30.17 Mn |
| Sep 30, 2024 | 30.17 Mn |
| Jun 30, 2024 | 31.57 Mn |
| Jun 30, 2024 | 31.57 Mn |
| Mar 31, 2024 | 42.54 Mn |
| Mar 31, 2024 | 42.54 Mn |
| Dec 31, 2023 | 36.93 Mn |
| Dec 31, 2023 | 36.93 Mn |
| Sep 30, 2023 | 34.44 Mn |
| Sep 30, 2023 | 34.44 Mn |
| Jun 30, 2023 | 46.53 Mn |
| Jun 30, 2023 | 46.53 Mn |